Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
NCT04421664 · McGill University Health Centre/Research Institute of the McGill University Health Centre · PHASE3 · terminated · last registry update 2024-10-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Request of Health Canada after publication of https://doi.org/10.7326/M20-4207” | – | Registry record, McGill University Health Centre/Research Institute of the McGill University Health Centre |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TLR7 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-09-25Results posted on the registry: BioMed Valley Discoveries, Inc, Ulixertinib + Hydroxychloroquine (NCT05221320)
- 2025-09-25Also stopped (terminated): BioMed Valley Discoveries, Inc, Ulixertinib + Hydroxychloroquine (NCT05221320)
- 2025-09-23Also stopped (terminated): Sanofi, Hydroxychloroquine SAR321068 + Placebo (NCT04333654)
- 2025-09-15Also stopped (withdrawn): London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Hydroxychloroquine + Placebo (NCT04397328)
- 2025-09-04Also stopped (suspended): National Institute of Allergy and Infectious Diseases (NIAID), 3M-052-AF + Alum + UVAX-1107 (NCT06905275)
- 2025-08-29Results posted on the registry: Milton S. Hershey Medical Center, Hydroxychloroquine + Placebo Oral Capsule (NCT03030118)
- 2025-07-11Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid (NCT07061717)
- 2025-07-04Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), INO-6160, 2 mg + Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg) (NCT05828095)
- 2025-06-27Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), BG505 SOSIP.664 gp140 + Placebo (NCT04177355)
- 2025-06-12Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Hydroxychloroquine + HCQ Placebo (NCT02603146)
- 2025-05-16Also stopped (withdrawn): Memorial Sloan Kettering Cancer Center, Hydroxychloroquine (NCT04379492)
- 2025-04-11Results posted on the registry: Patrick Hensley, Hydroxychloroquine Sulfate 200Mg Tab (NCT04011410)
- 2025-04-08Phase 3 first posted: University of Guadalajara, Will take 200mg/day magnesium oxide placebo. (NCT06915701)
- 2025-04-01Results posted on the registry: Abramson Cancer Center at Penn Medicine, Binimetinib Pill + Hydroxychloroquine Pill (NCT04735068)
- 2025-03-26Also stopped (withdrawn): National Institute of Allergy and Infectious Diseases (NIAID), CD4BS CH505M5 Pr-NP1 + CH505TF chTrimer (NCT06267872)
- 2025-03-10Also stopped (terminated): Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Hydroxychloroquine (NCT04363827)
- 2025-03-05Results posted on the registry: Abramson Cancer Center at Penn Medicine, Hydroxychloroquine + Everolimus (NCT03032406)
- 2025-02-17Results posted on the registry: M.D. Anderson Cancer Center, Hydroxychloroquine + Letrozole (NCT03774472)
- 2025-02-10Also stopped (terminated): ScandiBio Therapeutics AB, Hydroxychloroquine + Metabolic cofactor supplementation + Hydroxychloroquine + Sorbitol (NCT04573153)
- 2025-01-07Also stopped (withdrawn): Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland, Hydroxychloroquine + Mannitol (NCT04385264)
- 2024-12-18Results posted on the registry: Columbia University, Cobimetinib + Hydroxychloroquine (NCT04214418)
- 2024-12-18Also stopped (terminated): Columbia University, Cobimetinib + Hydroxychloroquine (NCT04214418)
- 2024-12-03Results posted on the registry: Gilead Sciences, Vesatolimod + Cobicistat (NCT05458102)
- 2024-12-03Also stopped (terminated): Gilead Sciences, Vesatolimod + Cobicistat (NCT05458102)
- 2024-11-27Results posted on the registry: Kimberly Perez, MD, Hydroxychloroquine Sulfate + LY3214996 (NCT04386057)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision